FDA agreed to use eGFR slope for Sangamo Therapeutics' approval after data was presented at a congress in Kyoto on September 4, 2025.
2 reports, 1 independent
Updated Sep 4
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA agreed to use eGFR slope for Sangamo Therapeutics' approval after data was presented at a congress in Kyoto on September 4, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Sangamo Therapeutics
American biotechnology company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 Totality of data supports potential for isar
- Unknown outlet